It is well known that periaticular and systemic osteoporosis are found in patients with rheumatoid arthritis (RA) associated with disease progression. We have studied the therapeutic effect of 1 a-OH-vitamin D
3 (VD
3) on osteoporosis observed in twenty patients with RA and other arthritides. These patients were given 1 μg VD
3 per day for one year. The degree of osteoporotic change was assessed by microdensitometry (MD) using MCI, GSmin, GSmax and XGS/D. Serum calcium (Ca), phosphorus (P), alkalin phosphatase (ALP) and parathyroid hormone (PTH) were measured simultaneously during this period. The clinical effects of VD
3 on disease activity of RA patients were evaluated by Lansbury's index. Microdensitography of the patients revealed improvement of osteoporosis in RA patients with scant bone change and early stage or no corticosteroid therapy (P<0.01-0.05) . No significant changes of serum levels of Ca, P, ALP or PTH were found. It has been observed clinical improvement in certain patients, although no significant alteration of Lansbury's index was evident. The results suggest that VD
3 is beneficial for osteoporosis in RA patients, especially in the patients with scant bone change and early stage or no corticosteroid therapy.
View full abstract